222 related articles for article (PubMed ID: 15507584)
1. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative.
Majumdar SR; Almasi EA; Stafford RS
JAMA; 2004 Oct; 292(16):1983-8. PubMed ID: 15507584
[TBL] [Abstract][Full Text] [Related]
2. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
Rapp SR; Espeland MA; Shumaker SA; Henderson VW; Brunner RL; Manson JE; Gass ML; Stefanick ML; Lane DS; Hays J; Johnson KC; Coker LH; Dailey M; Bowen D;
JAMA; 2003 May; 289(20):2663-72. PubMed ID: 12771113
[TBL] [Abstract][Full Text] [Related]
3. National use of postmenopausal hormone therapy: annual trends and response to recent evidence.
Hersh AL; Stefanick ML; Stafford RS
JAMA; 2004 Jan; 291(1):47-53. PubMed ID: 14709575
[TBL] [Abstract][Full Text] [Related]
4. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
Shumaker SA; Legault C; Rapp SR; Thal L; Wallace RB; Ockene JK; Hendrix SL; Jones BN; Assaf AR; Jackson RD; Kotchen JM; Wassertheil-Smoller S; Wactawski-Wende J;
JAMA; 2003 May; 289(20):2651-62. PubMed ID: 12771112
[TBL] [Abstract][Full Text] [Related]
5. Hormone therapy. A year in review.
Mayo Clin Womens Healthsource; 2003 Aug; 7(8):1-2. PubMed ID: 12925832
[TBL] [Abstract][Full Text] [Related]
6. Use of menopausal hormones in the United States, 1992 through June, 2003.
Wysowski DK; Governale LA
Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):171-6. PubMed ID: 15386701
[TBL] [Abstract][Full Text] [Related]
7. A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998.
Ma J; Stafford RS; Cockburn IM; Finkelstein SN
Clin Ther; 2003 May; 25(5):1503-17. PubMed ID: 12867225
[TBL] [Abstract][Full Text] [Related]
8. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
[TBL] [Abstract][Full Text] [Related]
9. Attitudes of Korean clinicians to postmenopausal hormone therapy after the Women's Health Initiative study.
Kang BM; Kim MR; Park HM; Yoon BK; Lee BS; Chung HW; Cho SH; Choi H; Kim JG
Menopause; 2006; 13(1):125-9. PubMed ID: 16607108
[TBL] [Abstract][Full Text] [Related]
10. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
11. Recent epidemiological evidence relevant to the clinical management of the menopause.
Shapiro S
Climacteric; 2007 Oct; 10 Suppl 2():2-15. PubMed ID: 17882666
[TBL] [Abstract][Full Text] [Related]
12. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
[TBL] [Abstract][Full Text] [Related]
13. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
Shapiro S
Climacteric; 2003 Dec; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
[TBL] [Abstract][Full Text] [Related]
14. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
[TBL] [Abstract][Full Text] [Related]
15. Estrogen plus progestin and risk of venous thrombosis.
Cushman M; Kuller LH; Prentice R; Rodabough RJ; Psaty BM; Stafford RS; Sidney S; Rosendaal FR;
JAMA; 2004 Oct; 292(13):1573-80. PubMed ID: 15467059
[TBL] [Abstract][Full Text] [Related]
16. Estrogen plus progestin and the risk of coronary heart disease.
Manson JE; Hsia J; Johnson KC; Rossouw JE; Assaf AR; Lasser NL; Trevisan M; Black HR; Heckbert SR; Detrano R; Strickland OL; Wong ND; Crouse JR; Stein E; Cushman M;
N Engl J Med; 2003 Aug; 349(6):523-34. PubMed ID: 12904517
[TBL] [Abstract][Full Text] [Related]
17. Women's Health Initiative estrogen plus progestin clinical trial: a study that does not allow establishing relevant clinical risks.
Aedo S; Cavada G; Blümel JE; Chedraui P; Fica J; Barriga P; Brantes S; Irribarra C; Vallejo M; Campodónico Í
Menopause; 2015 Dec; 22(12):1317-22. PubMed ID: 25968833
[TBL] [Abstract][Full Text] [Related]
18. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid.
Udell JA; Fischer MA; Brookhart MA; Solomon DH; Choudhry NK
J Bone Miner Res; 2006 May; 21(5):765-71. PubMed ID: 16734392
[TBL] [Abstract][Full Text] [Related]
19. The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program.
Hillman JJ; Zuckerman IH; Lee E
J Womens Health (Larchmt); 2004 Nov; 13(9):986-92. PubMed ID: 15665655
[TBL] [Abstract][Full Text] [Related]
20. Menopausal hormone therapy in a health maintenance organization before and after women's health initiative hormone trials termination.
Wegienka G; Havstad S; Kelsey JL
J Womens Health (Larchmt); 2006 May; 15(4):369-78. PubMed ID: 16724885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
